|
|
Post by jpg on Feb 28, 2015 22:43:30 GMT -5
Tripoley, Wow... You are good! Very interesting stuff. 1997 $ would be multiplied by 2 (or more?) for today dollars? Look below at 2013 sales. Top selling drugs of q4 2013: www.drugs.com/stats/top100/2013/salesHumalog (43): 1.46 billion $ Humalog KwikPen (71st best selling): 855 million $ NovoLog FlexPen (36th): 1.34 billion $ Novolog (37th): 1.32 billion $ I remember when Humalog and NovoLog came out (I was just out of residency) and 'experts' said there was no real market because they weren't any better (and possibly inferior) to Humulin and other insulins we no longer use very much (at least as prandials). The beauty of all this is that the above prandial insulins barely penetrate the type 2 market. Afrezza can and will eventually go after both.... |
|
|
|
Post by kball on Mar 1, 2015 6:03:44 GMT -5
Tripoley, Wow... You are good! Very interesting stuff. 1997 $ would be multiplied by 2 (or more?) for today dollars? Look below at 2013 sales.
Top selling drugs of q4 2013: www.drugs.com/stats/top100/2013/salesHumalog (43): 1.46 billion $ Humalog KwikPen (71st best selling): 855 million $ NovoLog FlexPen (36th): 1.34 billion $ Novolog (37th): 1.32 billion $ I remember when Humalog and NovoLog came out (I was just out of residency) and 'experts' said there was no real market because they weren't any better (and possibly inferior) to Humulin and other insulins we no longer use very much (at least as prandials). The beauty of all this is that the above prandial insulins barely penetrate the type 2 market. Afrezza can and will eventually go after both.... This list is an interesting read. Wouldnt have guessed Abilify would lead the pack, but perhaps it has most or all of that market to itself where as diabetes and heart related diseases have multiple meds that share the pie. Anyone have educated opinions as to when they think Afrezza might penetrate the type II market? And where on the list Afrezza might land if for the next 1-2 years we see primarily Type I conversion? |
|
|
|
Post by gomnkd on Mar 1, 2015 6:59:59 GMT -5
As a Product Afrezza is unique. The same thing applies to sales comparisons to Lantus, Nololog etc
1. The number of diabetic population has grown over last 15 yrs, at double digit worldwide.
2. Use of social media makes it easy for the product to be known. Use of CGM makes comparison easier.
3. Afrezza faces its unique challenges like perceived safety issue, time it takes to get "aha moment" for docs and pt.
|
|
|
|
Post by tripoley on Mar 1, 2015 7:51:55 GMT -5
Tripoley, Wow... You are good! Very interesting stuff. 1997 $ would be multiplied by 2 (or more?) for today dollars? Look below at 2013 sales. Top selling drugs of q4 2013: www.drugs.com/stats/top100/2013/salesHumalog (43): 1.46 billion $ Humalog KwikPen (71st best selling): 855 million $ NovoLog FlexPen (36th): 1.34 billion $ Novolog (37th): 1.32 billion $ I remember when Humalog and NovoLog came out (I was just out of residency) and 'experts' said there was no real market because they weren't any better (and possibly inferior) to Humulin and other insulins we no longer use very much (at least as prandials). The beauty of all this is that the above prandial insulins barely penetrate the type 2 market. Afrezza can and will eventually go after both.... I was just out of residency (FP) too when Humalog came out. I was using Humulin and at the time remember thinking "why do we need a faster acting insulin?" LOL. Of course I felt pretty comfortable with the Humulin and NPH onset and peaks, the Somogyi Phenomenon and diabetes in general. What I find surprising is if you look at the 2011 list Plavix is number two. I about laughed when the drug rep first told me Plavix had a 9% reduction of stroke over aspirin. Over populations that's pretty significant but $100+ for Plavix vs. a basically free aspirin? |
|
|
|
Post by tripoley on Mar 1, 2015 7:55:15 GMT -5
|
|
|
|
Post by jpg on Mar 1, 2015 14:09:18 GMT -5
That seems extremely optimistic... I think drug prices (and almost everything else especially in Canada) are going up faster then that? The average cost of a detached house in Vancouver and Toronto is now above 1 million $ (not a typo)... Now that is massive inflation (and a bubble). |
|
